![\"CAPVAXIVE\u00ae](\"https:\/\/www.merckvaccines.com\/capvaxive2-17\/wp-content\/uploads\/sites\/376\/2026\/03\/image-1.svg\")
![\"CAPVAXIVE\u00ae](\"https:\/\/www.merckvaccines.com\/capvaxive2-17\/wp-content\/uploads\/sites\/376\/2026\/03\/image.svg\" "\\"\\"")
<\/figure><\/div>\n<\/div>\n\n\n\nNew Indication<\/strong><\/h1><\/div>\n<\/div>\n<\/div>\n<\/div><\/div><\/div>\n\n\n\n\n<\/div>\n\n\n\n\n\n<\/div>\n\n\n\n\n\n<\/div>![\"\"\/](\"https:\/\/www.merckvaccines.com\/capvaxive2-17\/wp-content\/uploads\/sites\/376\/2026\/04\/Release_capv-home-desktop.png\")
<\/picture><\/p><\/figcaption>
Actor Portrayal<\/div><\/div><\/figure><\/div>\n\n\n\n<\/div>\n<\/div>\n\n\n\n<\/div>\n<\/div>\n\n\n\n<\/div>\n<\/div><\/div><\/div>\n\n\n\n\n\n\n<\/div>\n\n\n\nFDA approves an additional indication for CAPVAXIVE<\/strong><\/mark> <\/strong>in children and<\/span> adolescents aged 2 through 17 at increased risk for pneumococcal disease<\/mark><\/h2><\/div>\n\n\n\n<\/div>\n\n\n\nBefore administering CAPVAXIVE, please read the accompanying
Prescribing Information<\/mark><\/a>. The Patient Information<\/mark><\/a> <\/mark>also is available.<\/strong><\/p>\n\n\n\n<\/div>\n\n\n\n\n\n\nView Press Release<\/a><\/div>\n<\/div>\n<\/div>\n\n\n\n<\/div>\n<\/div>\n<\/div><\/div><\/div>\n\n\n\n<\/div>\n\n\n\n\nIndications and Usage<\/strong><\/h2><\/div>\n\n\n\nCAPVAXIVE\u00ae (Pneumococcal 21-valent Conjugate Vaccine) is indicated for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae<\/em> serotypes 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in individuals 2 through 17 years of age who are at increased risk for pneumococcal disease.<\/p>\n\n\n\n<\/div>\n\n\n\nSelect Safety Information<\/strong><\/h2><\/div>\n\n\n\nDo not administer CAPVAXIVE\u00ae (Pneumococcal 21-valent Conjugate Vaccine) to individuals with a history of a severe allergic reaction (eg, anaphylaxis) to any component of CAPVAXIVE or to diphtheria toxoid.<\/p>\n\n\n\n
<\/div>\n\n\n\nSyncope may occur with administration of injectable vaccines.<\/p>\n\n\n\n
<\/div>\n\n\n\nIndividuals with altered immunocompetence, including those receiving immunosuppressive therapy, may have a reduced immune response to CAPVAXIVE.<\/p>\n\n\n\n
<\/div>\n\n\n\nThe most commonly reported (>10%) solicited adverse reactions in individuals 2 through 17 years of age who are at increased risk for pneumococcal disease were: injection-site pain (67.7%), injection-site erythema (24.3%), fatigue (20.1%), injection-site swelling (18.8%), headache (17.1%), malaise (13.3%), and irritability (11.6%).<\/p>\n\n\n\n
<\/div>\n\n\n\nThe safety and effectiveness of CAPVAXIVE in individuals younger than 2 years of age have not been established.<\/p>\n\n\n\n
<\/div>\n\n\n\nVaccination with CAPVAXIVE may not protect all vaccine recipients.<\/p>\n\n\n\n
<\/div>\n\n\n\nBefore administering CAPVAXIVE, please read the accompanying Prescribing Information<\/a>. The Patient Information<\/a> also is available.<\/strong><\/p>\n<\/div><\/div><\/div>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":6437,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"_trash_the_other_posts":false,"editor_notices":[],"footnotes":""},"ga4_page_audience":[4],"ga4_page_birn_id":[],"ga4_page_branding":[21],"ga4_page_businessunit":[29],"ga4_page_campaign":[],"ga4_page_content_purpose":[71],"ga4_page_customer_journey_stage":[97],"ga4_page_customer_specialty":[148],"ga4_page_experience":[],"ga4_page_indication":[291],"ga4_page_material_intent":[320],"ga4_page_product":[546],"ga4_page_region":[550],"ga4_page_therapeuticarea":[],"class_list":["post-8","page","type-page","status-publish"],"yoast_head":"\nHelp Protect Certain Patients at Increased Risk of Pneumococcal Disease<\/title>\n<meta name=\"description\" content=\"Health care professionals can view the press release about a PCV indicated for certain patients at increased risk for pneumococcal disease. Prescribing Information and Patient Information also is available.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.merckvaccines.com\/capvaxive2-17\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Help Protect Certain Patients at Increased Risk of Pneumococcal Disease\" \/>\n<meta property=\"og:description\" content=\"Health care professionals can view the press release about a PCV indicated for certain patients at increased risk for pneumococcal disease. Prescribing Information and Patient Information also is available.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.merckvaccines.com\/capvaxive2-17\/\" \/>\n<meta property=\"og:site_name\" content=\"capvaxive2-17\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-09T15:43:02+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Help Protect Certain Patients at Increased Risk of Pneumococcal Disease","description":"Health care professionals can view the press release about a PCV indicated for certain patients at increased risk for pneumococcal disease. Prescribing Information and Patient Information also is available.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.merckvaccines.com\/capvaxive2-17\/","og_locale":"en_US","og_type":"article","og_title":"Help Protect Certain Patients at Increased Risk of Pneumococcal Disease","og_description":"Health care professionals can view the press release about a PCV indicated for certain patients at increased risk for pneumococcal disease. Prescribing Information and Patient Information also is available.","og_url":"https:\/\/www.merckvaccines.com\/capvaxive2-17\/","og_site_name":"capvaxive2-17","article_modified_time":"2026-07-09T15:43:02+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.merckvaccines.com\/capvaxive2-17\/","url":"https:\/\/www.merckvaccines.com\/capvaxive2-17\/","name":"Help Protect Certain Patients at Increased Risk of Pneumococcal Disease","isPartOf":{"@id":"https:\/\/www.merckvaccines.com\/capvaxive2-17\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.merckvaccines.com\/capvaxive2-17\/#primaryimage"},"image":{"@id":"https:\/\/www.merckvaccines.com\/capvaxive2-17\/#primaryimage"},"thumbnailUrl":"https:\/\/www.merckvaccines.com\/capvaxive2-17\/wp-content\/uploads\/sites\/376\/2026\/03\/image-1.svg","datePublished":"2026-03-10T13:02:04+00:00","dateModified":"2026-07-09T15:43:02+00:00","description":"Health care professionals can view the press release about a PCV indicated for certain patients at increased risk for pneumococcal disease. Prescribing Information and Patient Information also is available.","breadcrumb":{"@id":"https:\/\/www.merckvaccines.com\/capvaxive2-17\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.merckvaccines.com\/capvaxive2-17\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.merckvaccines.com\/capvaxive2-17\/#primaryimage","url":"https:\/\/www.merckvaccines.com\/capvaxive2-17\/wp-content\/uploads\/sites\/376\/2026\/03\/image-1.svg","contentUrl":"https:\/\/www.merckvaccines.com\/capvaxive2-17\/wp-content\/uploads\/sites\/376\/2026\/03\/image-1.svg","width":379,"height":140,"caption":"CAPVAXIVE\u00ae (Pneumococcal 21-valent Conjugate Vaccine) Logo"},{"@type":"BreadcrumbList","@id":"https:\/\/www.merckvaccines.com\/capvaxive2-17\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.merckvaccines.com\/capvaxive2-17\/"},{"@type":"ListItem","position":2,"name":"Homepage"}]},{"@type":"WebSite","@id":"https:\/\/www.merckvaccines.com\/capvaxive2-17\/#website","url":"https:\/\/www.merckvaccines.com\/capvaxive2-17\/","name":"capvaxive2-17","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.merckvaccines.com\/capvaxive2-17\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":[],"_links":{"self":[{"href":"https:\/\/www.merckvaccines.com\/capvaxive2-17\/wp-json\/wp\/v2\/pages\/8","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.merckvaccines.com\/capvaxive2-17\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.merckvaccines.com\/capvaxive2-17\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.merckvaccines.com\/capvaxive2-17\/wp-json\/wp\/v2\/users\/6437"}],"replies":[{"embeddable":true,"href":"https:\/\/www.merckvaccines.com\/capvaxive2-17\/wp-json\/wp\/v2\/comments?post=8"}],"version-history":[{"count":235,"href":"https:\/\/www.merckvaccines.com\/capvaxive2-17\/wp-json\/wp\/v2\/pages\/8\/revisions"}],"predecessor-version":[{"id":594,"href":"https:\/\/www.merckvaccines.com\/capvaxive2-17\/wp-json\/wp\/v2\/pages\/8\/revisions\/594"}],"wp:attachment":[{"href":"https:\/\/www.merckvaccines.com\/capvaxive2-17\/wp-json\/wp\/v2\/media?parent=8"}],"wp:term":[{"taxonomy":"ga4_page_audience","embeddable":true,"href":"https:\/\/www.merckvaccines.com\/capvaxive2-17\/wp-json\/wp\/v2\/ga4_page_audience?post=8"},{"taxonomy":"ga4_page_birn_id","embeddable":true,"href":"https:\/\/www.merckvaccines.com\/capvaxive2-17\/wp-json\/wp\/v2\/ga4_page_birn_id?post=8"},{"taxonomy":"ga4_page_branding","embeddable":true,"href":"https:\/\/www.merckvaccines.com\/capvaxive2-17\/wp-json\/wp\/v2\/ga4_page_branding?post=8"},{"taxonomy":"ga4_page_businessunit","embeddable":true,"href":"https:\/\/www.merckvaccines.com\/capvaxive2-17\/wp-json\/wp\/v2\/ga4_page_businessunit?post=8"},{"taxonomy":"ga4_page_campaign","embeddable":true,"href":"https:\/\/www.merckvaccines.com\/capvaxive2-17\/wp-json\/wp\/v2\/ga4_page_campaign?post=8"},{"taxonomy":"ga4_page_content_purpose","embeddable":true,"href":"https:\/\/www.merckvaccines.com\/capvaxive2-17\/wp-json\/wp\/v2\/ga4_page_content_purpose?post=8"},{"taxonomy":"ga4_page_customer_journey_stage","embeddable":true,"href":"https:\/\/www.merckvaccines.com\/capvaxive2-17\/wp-json\/wp\/v2\/ga4_page_customer_journey_stage?post=8"},{"taxonomy":"ga4_page_customer_specialty","embeddable":true,"href":"https:\/\/www.merckvaccines.com\/capvaxive2-17\/wp-json\/wp\/v2\/ga4_page_customer_specialty?post=8"},{"taxonomy":"ga4_page_experience","embeddable":true,"href":"https:\/\/www.merckvaccines.com\/capvaxive2-17\/wp-json\/wp\/v2\/ga4_page_experience?post=8"},{"taxonomy":"ga4_page_indication","embeddable":true,"href":"https:\/\/www.merckvaccines.com\/capvaxive2-17\/wp-json\/wp\/v2\/ga4_page_indication?post=8"},{"taxonomy":"ga4_page_material_intent","embeddable":true,"href":"https:\/\/www.merckvaccines.com\/capvaxive2-17\/wp-json\/wp\/v2\/ga4_page_material_intent?post=8"},{"taxonomy":"ga4_page_product","embeddable":true,"href":"https:\/\/www.merckvaccines.com\/capvaxive2-17\/wp-json\/wp\/v2\/ga4_page_product?post=8"},{"taxonomy":"ga4_page_region","embeddable":true,"href":"https:\/\/www.merckvaccines.com\/capvaxive2-17\/wp-json\/wp\/v2\/ga4_page_region?post=8"},{"taxonomy":"ga4_page_therapeuticarea","embeddable":true,"href":"https:\/\/www.merckvaccines.com\/capvaxive2-17\/wp-json\/wp\/v2\/ga4_page_therapeuticarea?post=8"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
<\/picture><\/p><\/figcaption>
FDA approves an additional indication for CAPVAXIVE<\/strong><\/mark> <\/strong>in children and<\/span> adolescents aged 2 through 17 at increased risk for pneumococcal disease<\/mark><\/h2><\/div>\n\n\n\n<\/div>\n\n\n\nBefore administering CAPVAXIVE, please read the accompanying
Prescribing Information<\/mark><\/a>. The Patient Information<\/mark><\/a> <\/mark>also is available.<\/strong><\/p>\n\n\n\n<\/div>\n\n\n\n\n\n\nView Press Release<\/a><\/div>\n<\/div>\n<\/div>\n\n\n\n<\/div>\n<\/div>\n<\/div><\/div><\/div>\n\n\n\n<\/div>\n\n\n\n\nIndications and Usage<\/strong><\/h2><\/div>\n\n\n\nCAPVAXIVE\u00ae (Pneumococcal 21-valent Conjugate Vaccine) is indicated for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae<\/em> serotypes 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in individuals 2 through 17 years of age who are at increased risk for pneumococcal disease.<\/p>\n\n\n\n<\/div>\n\n\n\nSelect Safety Information<\/strong><\/h2><\/div>\n\n\n\nDo not administer CAPVAXIVE\u00ae (Pneumococcal 21-valent Conjugate Vaccine) to individuals with a history of a severe allergic reaction (eg, anaphylaxis) to any component of CAPVAXIVE or to diphtheria toxoid.<\/p>\n\n\n\n
<\/div>\n\n\n\nSyncope may occur with administration of injectable vaccines.<\/p>\n\n\n\n
<\/div>\n\n\n\nIndividuals with altered immunocompetence, including those receiving immunosuppressive therapy, may have a reduced immune response to CAPVAXIVE.<\/p>\n\n\n\n
<\/div>\n\n\n\nThe most commonly reported (>10%) solicited adverse reactions in individuals 2 through 17 years of age who are at increased risk for pneumococcal disease were: injection-site pain (67.7%), injection-site erythema (24.3%), fatigue (20.1%), injection-site swelling (18.8%), headache (17.1%), malaise (13.3%), and irritability (11.6%).<\/p>\n\n\n\n
<\/div>\n\n\n\nThe safety and effectiveness of CAPVAXIVE in individuals younger than 2 years of age have not been established.<\/p>\n\n\n\n
<\/div>\n\n\n\nVaccination with CAPVAXIVE may not protect all vaccine recipients.<\/p>\n\n\n\n
<\/div>\n\n\n\nBefore administering CAPVAXIVE, please read the accompanying Prescribing Information<\/a>. The Patient Information<\/a> also is available.<\/strong><\/p>\n<\/div><\/div><\/div>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":6437,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"_trash_the_other_posts":false,"editor_notices":[],"footnotes":""},"ga4_page_audience":[4],"ga4_page_birn_id":[],"ga4_page_branding":[21],"ga4_page_businessunit":[29],"ga4_page_campaign":[],"ga4_page_content_purpose":[71],"ga4_page_customer_journey_stage":[97],"ga4_page_customer_specialty":[148],"ga4_page_experience":[],"ga4_page_indication":[291],"ga4_page_material_intent":[320],"ga4_page_product":[546],"ga4_page_region":[550],"ga4_page_therapeuticarea":[],"class_list":["post-8","page","type-page","status-publish"],"yoast_head":"\nHelp Protect Certain Patients at Increased Risk of Pneumococcal Disease<\/title>\n<meta name=\"description\" content=\"Health care professionals can view the press release about a PCV indicated for certain patients at increased risk for pneumococcal disease. Prescribing Information and Patient Information also is available.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.merckvaccines.com\/capvaxive2-17\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Help Protect Certain Patients at Increased Risk of Pneumococcal Disease\" \/>\n<meta property=\"og:description\" content=\"Health care professionals can view the press release about a PCV indicated for certain patients at increased risk for pneumococcal disease. Prescribing Information and Patient Information also is available.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.merckvaccines.com\/capvaxive2-17\/\" \/>\n<meta property=\"og:site_name\" content=\"capvaxive2-17\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-09T15:43:02+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Help Protect Certain Patients at Increased Risk of Pneumococcal Disease","description":"Health care professionals can view the press release about a PCV indicated for certain patients at increased risk for pneumococcal disease. Prescribing Information and Patient Information also is available.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.merckvaccines.com\/capvaxive2-17\/","og_locale":"en_US","og_type":"article","og_title":"Help Protect Certain Patients at Increased Risk of Pneumococcal Disease","og_description":"Health care professionals can view the press release about a PCV indicated for certain patients at increased risk for pneumococcal disease. Prescribing Information and Patient Information also is available.","og_url":"https:\/\/www.merckvaccines.com\/capvaxive2-17\/","og_site_name":"capvaxive2-17","article_modified_time":"2026-07-09T15:43:02+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.merckvaccines.com\/capvaxive2-17\/","url":"https:\/\/www.merckvaccines.com\/capvaxive2-17\/","name":"Help Protect Certain Patients at Increased Risk of Pneumococcal Disease","isPartOf":{"@id":"https:\/\/www.merckvaccines.com\/capvaxive2-17\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.merckvaccines.com\/capvaxive2-17\/#primaryimage"},"image":{"@id":"https:\/\/www.merckvaccines.com\/capvaxive2-17\/#primaryimage"},"thumbnailUrl":"https:\/\/www.merckvaccines.com\/capvaxive2-17\/wp-content\/uploads\/sites\/376\/2026\/03\/image-1.svg","datePublished":"2026-03-10T13:02:04+00:00","dateModified":"2026-07-09T15:43:02+00:00","description":"Health care professionals can view the press release about a PCV indicated for certain patients at increased risk for pneumococcal disease. Prescribing Information and Patient Information also is available.","breadcrumb":{"@id":"https:\/\/www.merckvaccines.com\/capvaxive2-17\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.merckvaccines.com\/capvaxive2-17\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.merckvaccines.com\/capvaxive2-17\/#primaryimage","url":"https:\/\/www.merckvaccines.com\/capvaxive2-17\/wp-content\/uploads\/sites\/376\/2026\/03\/image-1.svg","contentUrl":"https:\/\/www.merckvaccines.com\/capvaxive2-17\/wp-content\/uploads\/sites\/376\/2026\/03\/image-1.svg","width":379,"height":140,"caption":"CAPVAXIVE\u00ae (Pneumococcal 21-valent Conjugate Vaccine) Logo"},{"@type":"BreadcrumbList","@id":"https:\/\/www.merckvaccines.com\/capvaxive2-17\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.merckvaccines.com\/capvaxive2-17\/"},{"@type":"ListItem","position":2,"name":"Homepage"}]},{"@type":"WebSite","@id":"https:\/\/www.merckvaccines.com\/capvaxive2-17\/#website","url":"https:\/\/www.merckvaccines.com\/capvaxive2-17\/","name":"capvaxive2-17","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.merckvaccines.com\/capvaxive2-17\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":[],"_links":{"self":[{"href":"https:\/\/www.merckvaccines.com\/capvaxive2-17\/wp-json\/wp\/v2\/pages\/8","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.merckvaccines.com\/capvaxive2-17\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.merckvaccines.com\/capvaxive2-17\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.merckvaccines.com\/capvaxive2-17\/wp-json\/wp\/v2\/users\/6437"}],"replies":[{"embeddable":true,"href":"https:\/\/www.merckvaccines.com\/capvaxive2-17\/wp-json\/wp\/v2\/comments?post=8"}],"version-history":[{"count":235,"href":"https:\/\/www.merckvaccines.com\/capvaxive2-17\/wp-json\/wp\/v2\/pages\/8\/revisions"}],"predecessor-version":[{"id":594,"href":"https:\/\/www.merckvaccines.com\/capvaxive2-17\/wp-json\/wp\/v2\/pages\/8\/revisions\/594"}],"wp:attachment":[{"href":"https:\/\/www.merckvaccines.com\/capvaxive2-17\/wp-json\/wp\/v2\/media?parent=8"}],"wp:term":[{"taxonomy":"ga4_page_audience","embeddable":true,"href":"https:\/\/www.merckvaccines.com\/capvaxive2-17\/wp-json\/wp\/v2\/ga4_page_audience?post=8"},{"taxonomy":"ga4_page_birn_id","embeddable":true,"href":"https:\/\/www.merckvaccines.com\/capvaxive2-17\/wp-json\/wp\/v2\/ga4_page_birn_id?post=8"},{"taxonomy":"ga4_page_branding","embeddable":true,"href":"https:\/\/www.merckvaccines.com\/capvaxive2-17\/wp-json\/wp\/v2\/ga4_page_branding?post=8"},{"taxonomy":"ga4_page_businessunit","embeddable":true,"href":"https:\/\/www.merckvaccines.com\/capvaxive2-17\/wp-json\/wp\/v2\/ga4_page_businessunit?post=8"},{"taxonomy":"ga4_page_campaign","embeddable":true,"href":"https:\/\/www.merckvaccines.com\/capvaxive2-17\/wp-json\/wp\/v2\/ga4_page_campaign?post=8"},{"taxonomy":"ga4_page_content_purpose","embeddable":true,"href":"https:\/\/www.merckvaccines.com\/capvaxive2-17\/wp-json\/wp\/v2\/ga4_page_content_purpose?post=8"},{"taxonomy":"ga4_page_customer_journey_stage","embeddable":true,"href":"https:\/\/www.merckvaccines.com\/capvaxive2-17\/wp-json\/wp\/v2\/ga4_page_customer_journey_stage?post=8"},{"taxonomy":"ga4_page_customer_specialty","embeddable":true,"href":"https:\/\/www.merckvaccines.com\/capvaxive2-17\/wp-json\/wp\/v2\/ga4_page_customer_specialty?post=8"},{"taxonomy":"ga4_page_experience","embeddable":true,"href":"https:\/\/www.merckvaccines.com\/capvaxive2-17\/wp-json\/wp\/v2\/ga4_page_experience?post=8"},{"taxonomy":"ga4_page_indication","embeddable":true,"href":"https:\/\/www.merckvaccines.com\/capvaxive2-17\/wp-json\/wp\/v2\/ga4_page_indication?post=8"},{"taxonomy":"ga4_page_material_intent","embeddable":true,"href":"https:\/\/www.merckvaccines.com\/capvaxive2-17\/wp-json\/wp\/v2\/ga4_page_material_intent?post=8"},{"taxonomy":"ga4_page_product","embeddable":true,"href":"https:\/\/www.merckvaccines.com\/capvaxive2-17\/wp-json\/wp\/v2\/ga4_page_product?post=8"},{"taxonomy":"ga4_page_region","embeddable":true,"href":"https:\/\/www.merckvaccines.com\/capvaxive2-17\/wp-json\/wp\/v2\/ga4_page_region?post=8"},{"taxonomy":"ga4_page_therapeuticarea","embeddable":true,"href":"https:\/\/www.merckvaccines.com\/capvaxive2-17\/wp-json\/wp\/v2\/ga4_page_therapeuticarea?post=8"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
Before administering CAPVAXIVE, please read the accompanying CAPVAXIVE\u00ae (Pneumococcal 21-valent Conjugate Vaccine) is indicated for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae<\/em> serotypes 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in individuals 2 through 17 years of age who are at increased risk for pneumococcal disease.<\/p>\n\n\n\n Do not administer CAPVAXIVE\u00ae (Pneumococcal 21-valent Conjugate Vaccine) to individuals with a history of a severe allergic reaction (eg, anaphylaxis) to any component of CAPVAXIVE or to diphtheria toxoid.<\/p>\n\n\n\n Syncope may occur with administration of injectable vaccines.<\/p>\n\n\n\n Individuals with altered immunocompetence, including those receiving immunosuppressive therapy, may have a reduced immune response to CAPVAXIVE.<\/p>\n\n\n\n The most commonly reported (>10%) solicited adverse reactions in individuals 2 through 17 years of age who are at increased risk for pneumococcal disease were: injection-site pain (67.7%), injection-site erythema (24.3%), fatigue (20.1%), injection-site swelling (18.8%), headache (17.1%), malaise (13.3%), and irritability (11.6%).<\/p>\n\n\n\n The safety and effectiveness of CAPVAXIVE in individuals younger than 2 years of age have not been established.<\/p>\n\n\n\n Vaccination with CAPVAXIVE may not protect all vaccine recipients.<\/p>\n\n\n\n Before administering CAPVAXIVE, please read the accompanying Prescribing Information<\/a>. The Patient Information<\/a> also is available.<\/strong><\/p>\n<\/div><\/div><\/div>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":6437,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"_trash_the_other_posts":false,"editor_notices":[],"footnotes":""},"ga4_page_audience":[4],"ga4_page_birn_id":[],"ga4_page_branding":[21],"ga4_page_businessunit":[29],"ga4_page_campaign":[],"ga4_page_content_purpose":[71],"ga4_page_customer_journey_stage":[97],"ga4_page_customer_specialty":[148],"ga4_page_experience":[],"ga4_page_indication":[291],"ga4_page_material_intent":[320],"ga4_page_product":[546],"ga4_page_region":[550],"ga4_page_therapeuticarea":[],"class_list":["post-8","page","type-page","status-publish"],"yoast_head":"\n
Prescribing Information<\/mark><\/a>. The Patient Information<\/mark><\/a> <\/mark>also is available.<\/strong><\/p>\n\n\n\nIndications and Usage<\/strong><\/h2><\/div>\n\n\n\n
Select Safety Information<\/strong><\/h2><\/div>\n\n\n\n